Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention
This study has been completed.
Hospital de Cruces
First Posted: February 10, 2012
Last Update Posted: February 10, 2012
Information provided by (Responsible Party):
Roberto Matorras, Hospital de Cruces
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||September 2010|
|Primary Completion Date:||August 2008 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Matorras R, Andrés M, Mendoza R, Prieto B, Pijoan JI, Expósito A. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. Eur J Obstet Gynecol Reprod Biol. 2013 Oct;170(2):439-43. doi: 10.1016/j.ejogrb.2013.07.010. Epub 2013 Aug 8.